Showing results (241-250 of 283) with videos related to
Sort By:
Pageof 29
European Journal of Cancer (Oxford, England : 1990)|February 26, 2025
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized studyIgnace Vergote, Larry J Copeland, Toon Van Gorp, et al.Gynecologic Oncology|November 12, 2024
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Matthew A Powell, David Cibula, David M O'Malley, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 16, 2019
International radical trachelectomy assessment: IRTA studyGloria Salvo, Pedro T Ramirez, Mario Leitao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2022
A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control SetsChiara Herzog, Fátima Marín, Allison Jones, et al.Gynecologic Oncology|May 29, 2026
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trialMatthew A Powell, Henrik Roed, Lyndsay J Willmott, et al.Gynecologic Oncology|January 27, 2023
Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN studyDavid Cibula, Huseyin Akilli, Jiri Jarkovsky, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 20, 2024
Consensus on surgical technique for sentinel lymph node dissection in cervical cancerNicolò Bizzarri, Andreas Obermair, Heng-Cheng Hsu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2024
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient TumorsBrian M Slomovitz, David Cibula, Weiguo Lv, et al.The New England Journal of Medicine|December 6, 2023
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian CancerKathleen N Moore, Antoine Angelergues, Gottfried E Konecny, et al.The New England Journal of Medicine|July 3, 2024
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical CancerIgnace Vergote, Antonio González-Martín, Keiichi Fujiwara, et al.Pageof 29